Entering text into the input field will update the search result below

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Jul. 06, 2022 1:48 PM ETEnlivex Therapeutics Ltd. (ENLV)By: Anuron Mitra, SA News Editor
  • Israel-based Enlivex Therapeutics (NASDAQ:ENLV) on Wednesday said the first patient had been dosed in its phase 1/2 clinical trial evaluating its cell therapy Allocetra in combination with chemotherapy to treat cancer of the peritoneum.
  • ENLV stock +7.5% at $4.90 in afternoon trading.
  • The early-to-mid stage trial is expected to enroll about 12 patients across four cohorts and will evaluate the safety and potential preliminary efficacy of Allocetra in combination with chemotherapy in peritoneal cancer patients.
  • This is the initiation of the company's first oncology trial, according to ENLV CEO Oren Hershkovitz.
  • The trial is taking place at Israel's Sheba Medical Center hospital.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.